Asher Biotherapeutics is a biotechnology company pioneering a novel approach to immunotherapy through its proprietary cis-targeting platform. This innovative technology enables the selective activation of specific immune cell types, thereby enhancing therapeutic efficacy while minimizing off-target effects. By precisely engaging immune cells that drive desired responses, Asher Bio aims to overcome the limitations of conventional immunotherapies that often act indiscriminately on multiple cell types. Key Features and Functionality: - Cis-Targeting Platform: Asher Bio's platform involves designing therapies that engage two receptors on the same immune cell: an immunomodulatory receptor and a specific target receptor. This dual engagement ensures that the therapeutic effect is confined to the intended immune cell type, enhancing selectivity and reducing potential side effects. - Lead Program – Etakafusp Alfa (AB248): Formerly known as AB248, etakafusp alfa is a cis-targeted interleukin-2 (IL-2) therapy specifically engineered to activate CD8+ effector T cells. This selective activation is intended to boost anti-tumor responses without stimulating other immune cells that could lead to toxicity or immune suppression. - Clinical Development: Etakafusp alfa has demonstrated initial evidence of compelling anti-tumor activity with a well-tolerated safety profile in ongoing Phase 1a/1b clinical trials. - Pipeline Diversity: Beyond etakafusp alfa, Asher Bio's pipeline includes AB821, a CD8-targeted IL-21 immunotherapy, and early-stage programs targeting CAR-T cells, myeloid cells, and CD4+ T cells, showcasing the versatility of their cis-targeting approach. Primary Value and User Benefit: Asher Bio's cis-targeted immunotherapies address a critical need in the treatment of cancer, chronic viral infections, and autoimmune diseases by offering therapies that are both highly effective and well-tolerated. By selectively activating only the immune cells responsible for combating disease, these therapies aim to maximize therapeutic benefits while minimizing adverse effects. This precision not only enhances patient outcomes but also broadens the applicability of immunotherapies across various indications, potentially transforming the landscape of immune-based treatments.